Cargando…
Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines
A promising personal immunotherapy is autologous dendritic cells (DC) loaded ex vivo with autologous tumor antigens (ATA) derived from self-renewing autologous cancer cells. DC-ATA are suspended in granulocyte-macrophage colony stimulating factor at the time of each subcutaneous injection. Previousl...
Autores principales: | Dillman, Robert O., Nistor, Gabriel I., Keirstead, Hans S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294766/ https://www.ncbi.nlm.nih.gov/pubmed/37133853 http://dx.doi.org/10.1080/21645515.2023.2198467 |
Ejemplares similares
-
Portrait of an autologous cancer vaccine: Then and now
por: Berd, David
Publicado: (2023) -
Cytokine network analysis of immune responses before and after autologous dendritic cell and tumor cell vaccine immunotherapies in a randomized trial
por: Nistor, Gabriel I., et al.
Publicado: (2020) -
Phase III randomized, double-blinded, placebo-controlled multicenter trial of melapuldencil-t: autologous dendritic cells loaded with irradiated autologous tumor cells (dc-tc) in gm-csf in patients with metastatic melanoma
por: Dillman, Robert, et al.
Publicado: (2014) -
Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses
por: Dillman, Robert O., et al.
Publicado: (2018) -
Preliminary observations on soluble programmed cell death protein-1 as a prognostic and predictive biomarker in patients with metastatic melanoma treated with patient-specific autologous vaccines
por: Dillman, Robert O., et al.
Publicado: (2019)